NORDIC BIOTECH ADVISORS ApS: Financial statements 2014
CVR: 26123925
Source: annual report 2014, Danish Business Authority
01/01/2014 – 31/12/2014
NORDIC BIOTECH ADVISORS ApS (CVR 26123925) has filed annual accounts for 2014. In 2014, the company reported a gross profit of DKK 2,807,599 and a net result of DKK -161,863 compared with DKK 9,437 the year before. That is a decrease of 20.9% compared with the year before. Equity in the 2014 report amounted to DKK 1,213,059. The solvency ratio was 63.6%.
- Gross Profit
- DKK 2,807,599
- Profit/Loss
- DKK -161,863
- Equity
- DKK 1,213,059
- Total Assets
- DKK 1,908,184
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2014 | - | 2.8M | -162K | 1.2M | - |
| 2013 | - | 3.6M | 9K | 1.4M | - |
| 2012 | - | 3.8M | -63K | 1.4M | 2 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2014
NORDIC BIOTECH ADVISORS ApS has published its annual report for 2013. Gross profit came to DKK 3,550,848, and the net result was DKK 9,437.
As of June 20, 2014, DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of NORDIC BIOTECH ADVISORS ApS.
As of June 20, 2014, JUT NR. 2180 A/S has stepped down as auditor of NORDIC BIOTECH ADVISORS ApS.
About NORDIC BIOTECH ADVISORS ApS
NORDIC BIOTECH ADVISORS ApS is a Danish company of the type Anpartsselskab based in Hellerup, founded in 2001. The company is registered under the industry Andre aktiviteter i forbindelse med finansielle tjenesteydelser, undtagen forsikring og pensionsforsikring. The company was previously named NEXGEN BIOTECH ApS and NORDIC BIOTECH ApS. The management consists of Florian Schønharting. The board consists of Florian Schønharting and Jakob Mosegaard Larsen. The company is owned by TECH GROWTH INVEST ApS, C. HANSEN INVEST ApS and BVF/Nexgen Biotech, LP. The company has 2 employees (2026). In 2025, the company reported a gross profit of DKK 3,273,154 and a net result of DKK 360,368 compared with DKK -572,578 the year before. Equity in the 2025 report amounted to DKK 4,622,219.
